Skip to main content
Download PDF

The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer

Journal of Hematology & Oncology volume 10, Article number: 167 (2017) Cite this article

Abstract

The treatment paradigm of non-small cell lung cancer (NSCLC) has evolved into oncogene-directed precision medicine. Identifying actionable genomic alterations is the initial step towards precision medicine. An important scientific progress in molecular profiling of NSCLC over the past decade is the shift from the traditional piecemeal fashion to massively parallel sequencing with the use of next-generation sequencing (NGS). Another technical advance is the development of liquid biopsy with great potential in providing a dynamic and comprehensive genomic profiling of NSCLC in a minimally invasive manner. The integration of NGS with liquid biopsy has been demonstrated to play emerging roles in genomic profiling of NSCLC by increasing evidences. This review summarized the potential applications of NGS-based liquid biopsy in the diagnosis and treatment of NSCLC including identifying actionable genomic alterations, tracking spatiotemporal tumor evolution, dynamically monitoring response and resistance to targeted therapies, and diagnostic value in early-stage NSCLC, and discussed emerging challenges to overcome in order to facilitate clinical translation in future.

Background

In 1976, the relationship between genetic instability and tumorigenesis was proposed by Nowell [1]. Later on, progress in cancer genomics has further strengthened the notion that cancer is driven by various types of genomic alterations [2]. Global advances in sequencing techniques have refined an evolving genomic landscape of cancer. The technical revolution began with the era of first-generation sequencing, in which the Human Genome Project was an outstanding landmark by depicting the first 99.7% complete human genome with about 22,000 genes involved [3,4,5]. With the use of capillary-based instrument, methodologies of first-generation sequencing offered important discoveries of candidate genes [6,7,8], meanwhile raising concerns on cost-effectiveness and limitations in the scope of sequencing. Consequently, the sequencing pattern gradually developed into genomic scale fashion during the second half of last decade. Starting in 2005, next-generation sequencing (NGS) enabled a comprehensive profiling of cancer genome with unprecedented depth and breadth [2]. Collaborative projects such as The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) have characterized pan-cancer genetic abnormalities using NGS, cumulating knowledge of cancer genomics to accelerate discoveries of cancer causes and to improve diagnosis and treatment [9, 10]. Besides, emerging technical advances have made the cost of NGS to dramatically decrease and reach the point where an entire human genome could be sequenced for less than $1000 [11], increasing its accessibility to researchers.

NGS has three major advantages over the first-generation Sanger sequencing. The most outstanding one is its high-throughput, making testing of thousands of genes or even the whole genome possible. Additionally, NGS demonstrates excellent testing performance with compatibility of low-input DNA. Lastly, NGS appears to be more cost-effective in massively parallel sequencing [12, 13]. These abovementioned advantages have made NGS a promising testing for NSCLC, where multiple agents targeting various actionable genomic alterations are available [14,15,16,17,18,19,20,21,22]. Meanwhile, challenges of regulatory issues, assay validation, proficiency testing, and quality control still need to be overcome [23]. With more and more NGS platforms developed, standardization of reports from various test platforms is also urgently warranted.

Liquid biopsy is another revolutionary advance in genomic profiling of NSCLC. Currently, there are three types of circulating biomarkers that can be detected in liquid biopsy: circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes [24]. Among them, ctDNA is a potential surrogate for the entire tumor genome, and it is often referred to as “liquid biopsy” [25]. Liquid biopsy has advantages over traditional tissue biopsy in that the procedure is minimally invasive, is able to reflect a comprehensive genome landscape contributed by multiple tumor sites, and has the potential in serial monitoring [26]. Liquid biopsy demonstrated promising reference value in diagnosis and treatment of advanced NSCLC. Meanwhile, issues remain, including varying sensitivities and specificities between different platforms and lack of standardization of techniques and downstream processing [27].

The integration of NGS with liquid biopsy seems like the grafting in agriculture, which maximizes overall advantages (Fig. 1). NGS-based liquid biopsy might facilitate a minimally invasive and comprehensive genomic profiling of NSCLC that overcomes spatial heterogeneity arising from tissue biopsy and limitations in genomic information from candidate gene characterization. There is an increasing number of studies demonstrating the utility of NGS-based liquid biopsy in both advanced and early-stage NSCLC. Recent large-scale genomic profiling of advanced NSCLC by NGS-based ctDNA assays have demonstrated high concordance with matched tissue [28, 29], but it is noteworthy that the accuracy of this test in resectable stage NSCLC have reported to be much lower ranging from 23.3 to 50.4% [30, 31], possibly due to the low concentrations of ctDNA in early-stage patients. Along with efforts in improving the test sensitivity and investigations in diagnosis and monitoring NSCLC come practical challenges. This review summarizes the applications and emerging challenges of NGS-based liquid biopsy in patients with NSCLC.

Fig. 1
figure 1

Integration of NGS and liquid biopsy maximizes overall advantages

Full size image

Identifying actionable genomic alterations in patients with advanced NSCLC

The National Comprehensive Cancer Network guideline of NSCLC recommended testing for seven biomarkers amenable to targeted therapies, including epidermal growth factor receptor (EGFR) mutation, fusions in anaplastic lymphoma kinase (ALK), c-ros oncogene 1 receptor (ROS1) and RET proto-oncogene (RET), mesenchymal–epithelial transition (MET) amplification or MET exon 14 skipping mutation, human epidermal growth factor receptor-2 (HER2) mutation, and BRAF V600E mutation, indicating the necessity of multiplex sequencing. NGS-based ctDNA assay has demonstrated the feasibility of identifying multiple actionable genomic alterations with overall concordance rates with matched tissue ranging from 60 to 86% across various platforms in patients with advanced lung cancer [32,33,34,35,36,37]. A bias-corrected targeted NGS detected a broad range of actionable genomic alterations in the plasma, including ALK, ROS1, and RET rearrangements, HER2 insertions, and MET amplification in advanced NSCLC, with 100% specificity [34]. Another study using a semi-conductor-based NGS platform identified multiple biomarkers in plasma ctDNA including EGFR, KRAS, PIK3CA, and TP53 with an overall concordance rate of 76% with paired tissue DNA [32]. A proof-of-concept study from BioCAST/IFCT-1002 also reported the utility of NGS-based ctDNA assay to screen clinically relevant biomarkers including EGFR, KRAS, BRAF, ERBB2, and PI3KCA with an overall sensitivity of 58% and estimated specificity of 86% [33]. Notably, NGS-based ctDNA assay has demonstrated impressive performance of genotyping in cases of incomplete or negative tissue genotyping [29, 33, 34, 38,39,40]. In a recent study evaluating the utility of ctDNA analysis by digital NGS of over 8000 advanced NSCLC, additional actionable biomarkers such as EGFR mutations, ALK and ROS fusion, BRAF V600E mutation, and Met 14 skipping mutation were identified in 29% of unvaluable or under genotyped tissue cases [29]. Additionally, these evidences also suggested that NGS-based ctDNA assay might appear as a cost-effective approach to offer patients with advanced NSCLC more opportunities to be enrolled in innovative clinical studies involving multiple biomarkers analysis such as umbrella and cluster trials.

Among the abovementioned actionable genomic alterations, the performance of NGS in discovering druggable mutations is of clinical significance. Regarding EGFR testing, NGS-based ctDNA assay showed preferable sensitivity and specificity in detecting EGFR exon 19 deletion, exon 21 L858R mutation, and exon 20 T790M mutation. In TIGER-X study, a short footprint mutation enrichment NGS platform was used to interrogate EGFR activating mutations and T790M mutation in the urine and plasma samples from patients [39]. With tissue as a reference, the sensitivity of EGFR mutation detection in plasma was 87, 100, and 93% for exon 19 deletion, exon 21 L858R mutation, and exon 20 T790M mutation, respectively. The specificity of plasma EGFR mutation detection was 96% for exon 19 deletion, 100% for exon 21 L858R mutation, and 94% for exon 20 T790M mutation. The sensitivity of urine EGFR mutation detection in specimens that met the recommended volume of 90–100 ml also reached 83, 80, and 93% for exon 19 deletion, exon 21 L858R, and exon 20 T790M mutation, respectively. In a prospective study enrolling 288 NSCLC patients, the diagnostic specificity of NGS for exon 19 deletions and exon 21L858R mutation in the plasma were 98 and 94.1%, respectively, indicating a positive ctDNA result might enable direct recommendation of EGFR TKIs. The overall testing sensitivity was 72.7% in stage IIIB–IV patients [41]. Another issue that deserves to be addressed is the clinical accuracy of plasma EGFR assays as compared to matched tissue biopsies. Evidences from current largest data enrolling 229 advanced NSCLC patients with matched NGS-based ctDNA and tissue tests demonstrated that the positive predictive value (PPV) of ctDNA sequencing was 100% for EGFR exon 21 L858R mutation, 98% for EGFR exon 19 deletion, and 27% for EGFR exon 20 T790M mutation, suggesting latter acquisition of this resistance mutation [42]. The difference in plasma test accuracy between EGFR T790M mutation and EGFR-activating mutations was also reported in AURA3 study. Paired cobas plasma and tissue tests also demonstrated that the positive percent agreement of cobas plasma test with the cobas tissue test for EGFR T790M mutation detection was 51%, lower than that for EGFR activating mutations (exon 19 deletion, 82%; exon 21 L858R mutation, 68%) [43]. The abovementioned data highlighted the necessity of routine tissue biopsy in cases of EGFR T790M mutation-negative plasma assay.

Besides, the utility of NGS in plasma ALK testing was also demonstrated in several studies [34, 36, 38, 44]. Comparing two studies which performed non-invasive genotyping of ALK fusion by capture-based NGS, the test accuracy ranged from 68.8 to 91.7% for advanced NSCLC [38, 44]. Additionally, rare ALK fusion types, such as FAM179A-ALK and COL25A1-ALK, and ALK mutations including ALK L1152R, ALK I1171T, and ALK L1196M were also identified. With the advantages of simultaneous screening rare or even unknown ALK fusion patterns as well as somatic mutations, NGS-based ctDNA assay might not only provide a more comprehensive landscape of advanced ALK-positive NSCLC, but also offer more opportunities of ALK inhibitors to this subset of patients.

Of these druggable mutations, one important issue is whether the NGS ctDNA testing is comparable or even superior to routine methodologies. Evidence from multiple studies of EGFR mutation detection has demonstrated that the testing performance of NGS platforms is relatively comparable to polymerase chain reaction (PCR)-based and cobas platforms [45, 46]. Direct comparison was reported in AURA II study where cobas (a FDA-approved plasma EGFR test) and NGS were involved in plasma EGFR T790M testing. As compared to MiSeq NGS, the sensitivity and specificity of cobas was 91.5 and 91.1%, respectively. The concordance rate between the two methods was 91.3% [45]. Such performance was also comparable to that of BEAMING and digital droplet PCR (ddPCR) as reported in AURA I study. As compared to ARMS, the sensitivity and specificity ranged from 22.1 to 75% and 85 to 100%, respectively, in various studies [47]. NGS seemed to exhibit equivalent or even superior performance in plasma EGFR testing.

The biggest challenge facing NGS-based liquid biopsy is whether discoveries are really actionable in clinical practice. In case that multiple actionable genomic alterations are identified, how to distinguish the driver genes to be targeted from other passengers? Technically, this question might not be easily solved. With the background rates of mutation greatly vary among different patients and regions of the genome, NGS could not reliably indicate the driver genes from a number of passengers [48]. Besides, there is no universal consensus on the valid cut-off point of these actionable mutations being clinically relevant to take action. Several studies have reported cases with ultra-low mutation frequency in ctDNA [29, 33, 35]. NGS-based ctDNA assay of patients with IIIb/IV NSCLC showed that 46% of somatic mutations detected in ctDNA were observed at a frequency below 1% [35]. Whether targeting these actionable alterations with ultra-low frequency is clinically meaningful remains unknown. Thus, future studies deserve to further distinguish driver genetic alterations and define the valid cut-off point with clinical significance to make discoveries from NGS-based ctDNA assay becoming actionable in clinical practice. The APPLE Trial (NCT02856893), a randomized, three-arm, phase II study evaluating the feasibility and activity of osimertinib treatment on positive plasma EGFR T790M mutation in EGFR-mutant NSCLC patients might hopefully provide further evidence on this issue [49].

Discrepancies between liquid and tissue biopsy seem to be another challenge that hinders clinical translation. Both tissue-positive ctDNA-negative, and ctDNA-positive tissue-negative cases have been reported in several studies [33, 34, 38, 39]. Therefore, NGS-based liquid biopsy appears to complement the gold standard tissue biopsy. Integrating tissue testing and NGS-based liquid biopsy might be a promising strategy in molecular profiling of advanced NSCLC in the future. Meanwhile, due to the differences in NGS platforms and tissue assays across published studies, further evidences are needed to define the relationship of NGS-based ctDNA assays and tissue tests to facilitate clinical translation. Results from an ongoing observational study (NCT02620527) which compares the concordance between ctDNA assay and matched tissue test by FoundationOne is worth the expectation [50].

Dynamic monitoring of response and resistance to targeted therapies

Firstly, the value of NGS-based ctDNA analysis in predicting responses to targeted therapies has been demonstrated. Quantification of circulating specific tumor genes by NGS has been shown to be potential surrogate markers for patients under targeted treatments. Several studies suggested that the extent to which plasma and urine EGFR mutation levels drop after initiation of EGFR TKI might predict depth of response [39, 51, 52]. Of note, the ctDNA responses correlated well with radiologic responses in radiologic good responders, whereas correlation was poor in non-responders to EGFR TKIs [53]. In addition to quantification of specific tumor genes, the changes in molecular tumor load (MTL) detected by NGS correlated with or predicted all (95% CI, 82.0–99.8%) radiological and/or clinical responses except for cases without any genomic alteration detected [54].

Secondly, NGS-based ctDNA assay has also been reported to provide prognostic implications for patients with advanced NSCLC. ctDNA positive at diagnosis was suggested to be an independent marker of poor prognosis, with a median overall survival (OS) of 13.6 months versus 21.5 months (adjusted hazard ratio [HR] 1.82, p = 0.045). In addition, ctDNA clearance at first evaluation was also correlated with OS independently of Response Evaluation Criteria in Solid Tumors (RECIST) (HR 3.27, p < 0.001) [55]. Similarly, another prospective study further found that a cell-free DNA (cfDNA) concentration > 3 ng/l was associated with a decreased OS (median, 24 vs. 46 months; log-rank, p < 0.01) [36].

Thirdly, NGS-based ctDNA assay has also been successfully used for dynamically monitoring actionable genomic alterations [56,57,58]. Plasma EGFR monitoring by deep sequencing demonstrated that the mutation detection rate of EGFR exon 19 deletion/exon 21 L858R mutation was high at the initiation of EGFR-TKI (p = 0.001), suppressed during treatment course before disease progression, and elevated after the onset of disease progression (p = 0.023). The mutation detection rate of EGFR T790M was low until the onset of disease progression and elevated thereafter (p = 0.01) [56]. Another example of the ability of NGS-based ctDNA assay to dynamically monitor actionable genomic alternations was demonstrated in an ALK-positive case. The MAF of ALK fusion was detected at 0.91% pre-treatment and dropped to 0.41% at progression along with the emergence of F1174C which was detected at 1.0% [58].

Lastly, NGS-based ctDNA assay has refined a more heterogeneous resistance landscape to targeted therapies. Plasma NGS at pretreatment of rociletinib demonstrated a much more heterogeneous resistance scenario to first-line EGFR TKIs [59]. Concurrent with EGFR T790M mutation, multiple additional resistance mechanisms were observed in 46% of patients after failure from prior EGFR inhibitors, much higher than 5–15% in previous reports [60,61,62,63]. NGS-based ctDNA assay has also discovered novel resistance mechanisms to third-generation EGFR inhibitors. A well-known example is the discovery of EGFR C797S mutation, which mediates to osimertinib [64,65,66,67]. Intriguingly, NGS ctDNA analysis not only identified EGFR C797S mutation at disease progression, but also further demonstrated different genomic presentations of acquired EGFR C797S mutation, in cis or in trans with EGFR T790M mutation. In addition to the same DNA alteration seen in the tumor samples, plasma ctDNA analysis identified a second DNA alteration encoding the C797S mutation. Other novel resistance mechanisms to third-generation EGFR inhibitors such EGFR C797G mutation and EGFR L798I mutation have also been identified by NGS of pleural effusion and ctDNA, respectively [59, 68]. NGS-based ctDNA assay also unveiled a more comprehensive resistance landscape of ALK inhibitor crizotinib including F1174C/V, G1202R, L1198F, I1171T, and L1196M and potential novel resistance mechanisms of co-occurring SNVs in other genes that are absent in treatment-naïve patients [58].

The major hurdle in monitoring resistances is to identify dominant resistance mechanisms to guide what clinical action to be taken. Similar to tissue-based NGS genomic profiling, on condition that NGS-based ctDNA assay demonstrates a resistant landscape with two or more actionable genomic alterations, how should clinicians take action? One potential approach is to systematically use cellular characterization, clonal analysis, and protein structure to further validate discoveries from NGS-based ctDNA assay and moreover to suggest potential targeted agents. The feasibility of similar strategy has been demonstrated in a case report of advanced ALK-positive NSCLC. Systematic use of multiple assays not only validated that ALK C1156Y-L1198F mutations induced resistance to lorlatinib but also suggested the regained sensitivity to crizotinib, providing evidence on recalling crizotinib as a subsequent treatment to overcome lorlatinib resistance [69].

Another emerging challenge is how to refine treatment strategy according to ctDNA mutational dynamics. An innovative strategy has been proposed in a trial which plans to monitor tumor resistance by ctDNA and tailor treatment based on abundance of EGFR T790M mutation in plasma [70]. When the levels of EGFR T790M mutation reduce, they will switch to a first-generation EGFR inhibitor, and when EGFR T790M mutation levels rise, the researchers will switch back to osimertinib. Collectively, endeavors to investigate novel treatment strategies based on ctDNA dynamics is promising; however, present evidence are not yet sufficient to transform clinical practice.

Diagnostic value in early-stage NSCLC

The potential of NGS-based ctDNA in screening for early-stage NSCLC has been demonstrated in several studies. The median yield of cfDNAs was demonstrated to be significantly higher in patients with early-stage lung adenocarcinomas, as compared to healthy controls (4.9 vs. 2.32 ng, p = 0.003). In addition, Log2 ratio-based CNV analysis demonstrated subtle but detectable differences in cfDNAs between patients and controls, suggesting that such assay may sensitively distinguish early-stage disease when in combination with other existing screening strategies such as low-dose CT scanning [71]. In addition, the feasibility of detecting genomic alterations in ctDNA/cfDNA by NGS for early-stage NSCLC have been reported. A prospective study conducted in surgical stage I NSCLC showed that the overall concordance rate between tDNA and matched NGS-based ctDNA assay was 50.4%, with a sensitivity of 53.8%, a specificity of 47.3%, and a plasma PPV of 53.2% [31]. As the test sensitivity is a key point in detecting early-stage NSCLC with low levels of ctDNA/cfDNA, interpreting these results has to be careful and further evaluation are warranted. In addition to identifying early-stage NSCLC, the ability of detecting both ubiquitous and heterogeneous SNVs by NGS-based cfDNA assay has also been reported in a pilot study, revealing intratumor heterogeneity in early-stage NSCLC [72]. Moreover, a promising strategy that enabled early detection and mapping the primary growth site of a tumor was recently demonstrated by characterization of methylation haplotyping in plasma cfDNA via the combined use of whole-genome bisulfite sequencing and other analysis in 59 patients with lung or colorectal cancer [73].

The use of NGS-based liquid biopsy in screening for early-stage NSCLC is challenging, as an increased risk of false-positive results is more likely with the increased sensitivity [74]. Clinical concerns on early-stage cancer detection by ctDNA have arisen [75], whether oncologists should take action or follow “watch and wait” strategy in case of positive screening results. Integrating the use of low-dose CT screening with NGS-based liquid biopsy might hopefully reduce the lead-time bias and facilitate early detection in high-risk population for lung cancer. However, how shall clinicians take action in case one has positive findings from NGS-based liquid biopsy but no imaging abnormalities remains a challenge to be solved in the future.

Tracking spatiotemporal tumor evolution

With the application of NGS, intratumoral clonal heterogeneity has been demonstrated to be a key factor fostering therapeutic resistance to anti-cancer treatments [76]. Spatiotemporal tumor evolution undertreatment selection might be the root of intratumoral heterogeneity. NGS-based liquid biopsy has appeared to be a valuable approach to decipher the spatiotemporal tumor evolution of lung cancer. Two evolving patterns of MTL have been identified in a recent study which performed serial monitor of ctDNA from 38 patients with advanced lung cancer (NSCLC accounting for 95%) by digital NGS [54]. One pattern is the clonal changes while receiving targeted therapy; the other is the global changes to PD-1 checkpoint inhibitors, chemotherapy, or radiation. Additionally, a large observational study called Tracking Lung Cancer Evolution Through Treatment (TRACERx) has been launched (NCT01888601) to depict the spatiotemporal evolution trace of early-stage lung cancer [77]. A bespoke multiplex-PCR NGS approach to ctDNA profiling in the first 100 TRACERx has demonstrated the feasibility to characterizing the subclonal dynamics of relapsing NSCLC and identifying the emerging subclones prior to clinical recurrence. By following both clonal and subclonal single nucleotide variants (SNVs) present in pre-operative plasma and at the time of recurrence, the study found that 48% of patients had ≥ 2 detectable SNVs in ctDNA. The median interval between ctDNA detection and relapse detected by CT scanning was 70 days. Besides, the phylogenetic origin of the metastatic subclone could be traced [78]. Just as the Chinese strategist Sun Tzu ever said, “Know yourself and know your enemy, you could win every war”. NGS-based liquid biopsy might potentially contribute to piecing together a more precise picture of how tumor evolve and help us evolve our treatment strategies accordingly to reshape this heterogeneous population.

Along with deeper insights into lung cancer come novel challenges. As mentioned in the study of ctDNA profiling in the first 100 TRACERx, the estimated cost per patient for sequencing of a single tumor region, synthesis of a patient-specific assay panel, and profiling of five plasma sample is $1750. How to incorporate novel findings from these high-cost studies into improving clinical outcomes is a key practical question. One potential approach might be adapting treatment strategy according to evolutionary dynamics to improve the efficacy of current available agents. DARWIN I study (NCT02183883), which involves patients registered to TRACERx study, will assess if targeting EGFR and HER2 mutations by afatinib in NSCLC is more effective when these mutations are truncal dominant mutations (≥ 50%), as opposed to non-dominant (≥ 5 to < 50%) or low-frequency mutations (< 5%) [79]. DARWIN II (NCT02314481) is an exploratory phase II study examining the role of intratumor heterogeneity and predicted neo-antigens on the anti-tumor activity of anti-PDL1 immunotherapy [80]. Relationship between intratumor heterogeneity and cfDNA/CTCs will be explored, which may develop tools for patient selection and monitoring to be examined in future studies. Despite these studies are still in infancy, such endeavors might potentially refine treatment strategies to improve patient outcomes in the near future.

Conclusions

The integration of NGS and liquid biopsy might complement the gold standard tissue testing and thrive to be a promising candidate of genomic profiling in NSCLC. NGS-based ctDNA assay might be applied in identifying actionable genomic alterations, dynamically monitoring response and resistance to targeted agents, prescreening early-stage lung cancer, and tracking spatiotemporal evolution of lung cancer (Fig. 2). However, challenges remain such as difficulties in distinguishing clinical meaningful driver genomic alterations, defining valid cut-off frequency of being clinically relevant, obstacles in identifying dominant resistance mechanisms, when to take action in case of positive ctDNA screening results in early-stage NSCLC, and cost-effectiveness of tacking tumor evolution. Further studies are warranted to overcome these challenges to define the clinical utility of NGS-based liquid biopsy.

Fig. 2
figure 2

Current applications and future development of NGS-based liquid biopsy in lung cancer

Full size image

Abbreviations

ALK:

Anaplastic lymphoma kinase

ARMS:

Amplification Refractory Mutation System

CTCs:

Circulating tumor cells

ctDNA:

Circulating tumor DNA

EGFR:

Epidermal growth factor receptor

HER2:

Human epidermal growth factor receptor-2

HR:

Hazard ratio

ICGC:

The International Cancer Genome Consortium

MAF:

Mutant allele fraction

MET:

Mesenchymal–epithelial transition

MTL:

Molecular tumor load

NGS:

Next-generation sequencing

NSCLC:

Non-small cell lung cancer

OS:

Overall survival

PCR:

Polymerase chain reaction

PPV:

Positive predictive value

RECIST:

Response Evaluation Criteria in Solid Tumors

RET:

RET proto-oncogene

ROS1:

c-ros oncogene 1 receptor

TCGA:

The Cancer Genome Atlas

tDNA:

Tissue DNA

References

  1. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194:23–8.

    Article  CAS  PubMed  Google Scholar 

  2. MacConaill LE. Existing and emerging technologies for tumor genomic profiling. J Clin Oncol. 2013;31:1815–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Green P. Against a whole-genome shotgun. Genome Res. 1997;7:410–7.

    Article  CAS  PubMed  Google Scholar 

  4. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860–921.

    Article  CAS  PubMed  Google Scholar 

  5. Evans JP. The Human Genome Project at 10 years: a teachable moment. Genet Med. 2010;12:477.

    Article  PubMed  Google Scholar 

  6. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–39.

    Article  CAS  PubMed  Google Scholar 

  7. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–500.

    Article  CAS  PubMed  Google Scholar 

  8. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101:13306–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Zhang J, Baran J, Cros A, Guberman JM, Haider S, Hsu J, et al. International Cancer Genome Consortium Data Portal—a one-stop shop for cancer genomics data. Database (Oxford). 2011;2011:bar026.

    Google Scholar 

  10. Cancer Genome Atlas Research N, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013;45:1113–20.

    Article  Google Scholar 

  11. Kruglyak KM, Lin E, Ong FS. Next-generation sequencing and applications to the diagnosis and treatment of lung cancer. Adv Exp Med Biol. 2016;890:123–36.

    Article  PubMed  Google Scholar 

  12. Meldrum C, Doyle MA, Tothill RW. Next-generation sequencing for cancer diagnostics: a practical perspective. Clin Biochem Rev. 2011;32:177–95.

    PubMed  PubMed Central  Google Scholar 

  13. Luthra R, Chen H, Roy-Chowdhuri S, Singh RR. Next-generation sequencing in clinical molecular diagnostics of cancer: advantages and challenges. Cancers (Basel). 2015;7:2023–36.

    Article  Google Scholar 

  14. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57.

    Article  CAS  PubMed  Google Scholar 

  15. Ke EE, Wu YL. Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence. Ther Adv Respir Dis. 2016;10:256–64.

    Article  CAS  PubMed  Google Scholar 

  16. Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Zhang YC, Zhou Q, Wu YL. Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC. Expert Opin Pharmacother. 2016;17:1693–701.

    Article  CAS  PubMed  Google Scholar 

  18. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371:1963–71.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Gainor JF, Shaw AT. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist. 2013;18:865–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Ou SH, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol. 2011;6:942–6.

    Article  PubMed  Google Scholar 

  21. De Greve J, Teugels E, Geers C, Decoster L, Galdermans D, De Mey J, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer. 2012;76:123–7.

    Article  CAS  PubMed  Google Scholar 

  22. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373:726–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Schrijver I, Aziz N, Farkas DH, Furtado M, Gonzalez AF, Greiner TC, et al. Opportunities and challenges associated with clinical diagnostic genome sequencing: a report of the Association for Molecular Pathology. J Mol Diagn. 2012;14:525–40.

    Article  CAS  PubMed  Google Scholar 

  24. Masuda T, Hayashi N, Iguchi T, Ito S, Eguchi H, Mimori K. Clinical and biological significance of circulating tumor cells in cancer. Mol Oncol. 2016;10:408–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 2015;61:112–23.

    Article  CAS  PubMed  Google Scholar 

  26. Matikas A, Syrigos KN, Agelaki S. Circulating biomarkers in non-small-cell lung cancer: current status and future challenges. Clin Lung Cancer. 2016;17:507–16.

    Article  CAS  PubMed  Google Scholar 

  27. Levy B, Hu ZI, Cordova KN, Close S, Lee K, Becker D. Clinical utility of liquid diagnostic platforms in non-small cell lung cancer. Oncologist. 2016;21:1121–30.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Zill OA, Mortimer S, Banks KC, Nagy RJ, Chudova D, Jackson C, et al. Somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA. J Clin Oncol. 2016;34(suppl 15):abstr 587s.

    Google Scholar 

  29. Mack P, Banks K, Riess J, Zill O, Stefanie Mortimer DC, Odegaard J, et al. Clinical utility of circulating tumor DNA (ctDNA) analysis by digital next generation sequencing of over 5,000 advanced NSCLC patients. J Thorac Oncol. 2017;12(Suppl 1):135S.

    Google Scholar 

  30. Ohira T, Sakai K, Matsubayashi J, Kajiwara N, Kakihana M, Hagiwara M, et al. Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer. Cancer Sci. 2016;107:1660–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Chen KZ, Lou F, Yang F, Zhang JB, Ye H, Chen W, et al. Circulating tumor DNA detection in early-stage non-small cell lung cancer patients by targeted sequencing. Sci Rep. 2016;6:31985.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Xu S, Lou F, Wu Y, Sun DQ, Zhang JB, Chen W, et al. Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients. Cancer Lett. 2016;370:324–31.

    Article  CAS  PubMed  Google Scholar 

  33. Couraud S, Vaca-Paniagua F, Villar S, Oliver J, Schuster T, Blanche H, et al. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002. Clin Cancer Res. 2014;20:4613–24.

    Article  CAS  PubMed  Google Scholar 

  34. Paweletz CP, Sacher AG, Raymond CK, Alden RS, O'Connell A, Mach SL, et al. Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients. Clin Cancer Res. 2016;22:915–22.

    Article  CAS  PubMed  Google Scholar 

  35. Remon J. Evaluation of liquid biopsies for molecular profiling and monitoring in nonsmall cell lung cancer (NSCLC) patients. J Clin Oncol. 2016;34(suppl 15):594s.

    Google Scholar 

  36. Thompson JC, Yee SS, Troxel AB, Savitch SL, Fan R, Balli D, et al. Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA. Clin Cancer Res. 2016;22:5772–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Yao Y, Liu J, Li L, Yuan Y, Nan K, Wu X, et al. Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer. Oncotarget. 2017;8:2130–40.

    PubMed  Google Scholar 

  38. Wang Y, Tian PW, Wang WY, Wang K, Zhang Z, Chen BJ, et al. Noninvasive genotyping and monitoring of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer by capture-based next-generation sequencing. Oncotarget. 2016;7:65208–17.

    PubMed  PubMed Central  Google Scholar 

  39. Reckamp KL, Melnikova VO, Karlovich C, Sequist LV, Camidge DR, Wakelee H, et al. A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma. J Thorac Oncol. 2016;11:1690–700.

    Article  PubMed  Google Scholar 

  40. Villaflor V, Won B, Nagy R, Banks K, Lanman RB, Talasaz A, et al. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Oncotarget. 2016;7:66880–91.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Uchida J, Kato K, Kukita Y, Kumagai T, Nishino K, Daga H, et al. Diagnostic accuracy of noninvasive genotyping of EGFR in lung cancer patients by deep sequencing of plasma cell-free DNA. Clin Chem. 2015;61:1191–6.

    Article  CAS  PubMed  Google Scholar 

  42. Mack PC, Banks KC, Zill OA, Mortimer SA, Chudova DI, Odegaard J, et al. O.02: plasma next generation sequencing of over 5,000 advanced non-small cell lung cancer patients with clinical correlations. J Thorac Oncol. 2016;11:S168–S9.

    Article  PubMed  Google Scholar 

  43. Wu YL, Jenkins S, Ramalingam S, Han J-Y, Delmonte A, Hsia T-C, et al. Osimertinib vs platinum-pemetrexed for T790M mutation positive advanced NSCLC (AURA3): plasma ctDNA analysis. J Thorac Oncol. 2017;12(Suppl):S195–6.

    Google Scholar 

  44. Cui S, Zhang W, Xiong L, Pan F, Niu Y, Chu T, et al. Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer. Oncotarget. 2017;8:2771–80.

    PubMed  Google Scholar 

  45. Jenkins S, Yang JC-H, Ramalingam SS, Yu K, Patel S, Weston S, et al. Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (aNSCLC). 2016 ELCC 134O_PR.

    Google Scholar 

  46. Kang X, Xu T, Xu G, Chen K-N. Comparison of four leading technologies for detecting EGFR mutations in circulating tumor DNA from patients with non-small cell lung carcinoma. J Thorac Oncol. 2017;12(Suppl 1):S626.

    Google Scholar 

  47. Sun W, Yuan X, Tian Y, Wu H, Xu H, Hu G, et al. Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer. J Hematol Oncol. 2015;8:95.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339:1546–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Remon J, Menis J, Hasan B, Peric A, De Maio E, Novello S, et al. The APPLE trial: feasibility and activity of AZD9291 (osimertinib) treatment on Positive PLasma T790M in EGFR-mutant NSCLC patients. EORTC 1613. Clin Lung Cancer. 2017; doi:10.1016/j.cllc.2017.02.005.

  50. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/study/NCT02620527?term=NCT02620527&rank=1. Last accessed 22 July 2017.

  51. Karlovich C, Goldman JW, Sun JM, Mann E, Sequist LV, Konopa K, et al. Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase I study of rociletinib (CO-1686). Clin Cancer Res. 2016;22:2386–95.

    Article  CAS  PubMed  Google Scholar 

  52. Mok T, Wu YL, Lee JS, Yu CJ, Sriuranpong V, Sandoval-Tan J, et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res. 2015;21:3196–203.

    Article  CAS  PubMed  Google Scholar 

  53. Imamura F, Uchida J, Kukita Y, Kumagai T, Nishino K, Inoue T, et al. Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer. Lung Cancer. 2016;94:68–73.

    Article  PubMed  Google Scholar 

  54. Zhao Y, Gong J, Ma W, Banks K, Wen H, Moore EH, et al. Serial quantitative assessment of plasma circulating tumor DNA by digital NGS in patients with lung cancer. J Thorac Oncol. 2017;12(Suppl 1):S120–1.

    Google Scholar 

  55. Pecuchet N, Zonta E, Didelot A, Combe P, Thibault C, Gibault L, et al. Base-position error rate analysis of next-generation sequencing applied to circulating tumor DNA in non-small cell lung cancer: a prospective study. PLoS Med. 2016;13:e1002199.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Uchida J, Imamura F, Kukita Y, Oba S, Kumagai T, Nishino K, et al. Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment. Cancer Sci. 2016;107:353–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Zhou Q, Yang JJ, Chen ZH, Zhang XC, Yan HH, Xu CR, et al. Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial. J Hematol Oncol. 2016;9:86.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Ihuegbu N, Banks KC, Fairclough SR, Zill OA, Chudova D, Lanman RB, et al. Non-invasive detection of crizotinib resistance in ALK-rearranged lung adenocarcinoma directs treatment with next-generation ALK inhibitors. J Clin Oncol. 2016;34(suppl 15):abstr e20643.

    Google Scholar 

  59. Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun. 2016;7:11815.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3:75ra26.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A. 2012;109:E2127–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Suda K, Murakami I, Katayama T, Tomizawa K, Osada H, Sekido Y, et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res. 2010;16:5489–98.

    Article  CAS  PubMed  Google Scholar 

  64. Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21:560–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Wang S, Tsui ST, Liu C, Song Y, Liu D. EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer. J Hematol Oncol. 2016;9:59.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Wang S, Song Y, Yan F, Liu D. Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors. Front Med. 2016;10:383–8.

    Article  PubMed  Google Scholar 

  67. Fairclough SR, Zill OA, Chudova D, Lee CE, Lanman RB, Banks KC, et al. Case series of EGFR C797S mutations in non-small cell lung cancer identified with cell-free circulating tumor DNA next generation sequencing. J Clin Oncol. 2016;34(suppl 15):abstr e23021.

    Google Scholar 

  68. Menon R, Muller J, Schneider P, Lakis S, Thress K, Wolf J, et al. A novel EGFR(C797) variant detected in a pleural biopsy specimen from an osimertinib-treated patient using a comprehensive hybrid capture-based next-generation sequencing assay. J Thorac Oncol. 2016;11:e105–7.

    Article  PubMed  Google Scholar 

  69. Shaw AT, Friboulet L, Leshchiner I, Gainor JF, Bergqvist S, Brooun A, et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med. 2016;374:54–61.

    Article  CAS  PubMed  Google Scholar 

  70. Willyard C. Cancer therapy: an evolved approach. Nature. 2016;532:166–8.

    Article  CAS  PubMed  Google Scholar 

  71. Xia S, Huang CC, Le M, Dittmar R, Du M, Yuan T, et al. Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls. Lung Cancer. 2015;90:78–84.

    Article  PubMed  Google Scholar 

  72. Jamal-Hanjani M, Wilson GA, Horswell S, Mitter R, Sakarya O, Constantin T, et al. Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. Ann Oncol. 2016;27:862–7.

    Article  CAS  PubMed  Google Scholar 

  73. Guo S, Diep D, Plongthongkum N, Fung HL, Zhang K, Zhang K. Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA. Nat Genet. 2017;49:635–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Malapelle U, Pisapia P, Rocco D, Smeraglio R, di Spirito M, Bellevicine C, et al. Next generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patients. Transl Lung Cancer Res. 2016;5:505–10.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Lancet O. Liquid cancer biopsy: the future of cancer detection? Lancet Oncol. 2016;17:123.

    Article  Google Scholar 

  76. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Jamal-Hanjani M, Hackshaw A, Ngai Y, Shaw J, Dive C, Quezada S, et al. Tracking genomic cancer evolution for precision medicine: the lung TRACERx study. PLoS Biol. 2014;12:e1001906.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545:446–51.

    Article  CAS  PubMed  Google Scholar 

  79. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02183883?term=Darwin&rank=5. Last accessed 22 July 2017.

  80. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02314481?term=Darwin&rank=1. Last accessed 22 July 2017.

Download references

Acknowledgements

This work was supported by the National Key Research and Development Program of China (Grant No.2016YFC1303800), Guangdong Provincial Key Laboratory of Lung Cancer Translational Medicine (Grant No. 2012A061400006), and Natural Science Foundation of Guangdong Province (Grant No. 2015A030313539).

Availability of data and materials

The material supporting the conclusion of this review has been included within the article.

Author information

Authors and Affiliations

  1. Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road, Guangzhou, Guangdong, 510080, People’s Republic of China

    Yi-Chen Zhang, Qing Zhou & Yi-Long Wu

Authors
  1. Yi-Chen Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qing Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yi-Long Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YW designed the review. YZ and YW drafted the manuscript and finalized the figure. QZ provided useful suggestions. All authors read and approved final manuscript.

Corresponding author

Correspondence to Yi-Long Wu.

Ethics declarations

Ethics approval and consent to participate

This is not applicable for this review.

Consent for publication

This is not applicable for this review.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, YC., Zhou, Q. & Wu, YL. The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer. J Hematol Oncol 10, 167 (2017). https://0-doi-org.brum.beds.ac.uk/10.1186/s13045-017-0536-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://0-doi-org.brum.beds.ac.uk/10.1186/s13045-017-0536-6

Keywords

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us